# Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

> **NCT06180174** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- B Cell Lymphoma
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** MC-1-50

## Key facts

- **NCT ID:** NCT06180174
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180174, "Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06180174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*